Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 27, 2025
Daily News
February 27, 2025
- AstraZeneca Rolling Out “Unify” App for Decentralized Trials in Japan
February 27, 2025
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
- Daiichi Eyes 9 New Indications for 2 Lead ADCs, Tripling Patient Number by 2026
February 27, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
February 27, 2025
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…